Skip to main content

Unable to load price data. Sorry.

¯\_(ツ)_/¯

Alcobra Pharmaceuticals (NASDAQ:ADHD.DL)

CAPS Rating: No stars

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform
 

All-Star Players

0 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ADHD.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

superstar (99.95)
Submitted January 17, 2017

Oh my, what an incredible surprise, Biotech Alcobra LTD, had its ADHD drug fail to meet its primary endpoint in a phase 3 trial. I really hope no caps members were holding this one long before today. However, if this one continues to drift lower, I… More

zzlangerhans (99.42)
Submitted October 09, 2015

If there's a thesis for buying Alcobra, it must be that the company will achieve success in the second go round phase III trial of MDX for adult ADHD (are we sure this is a real disease?). This is a rather tough sell given failure in the first phase… More

NASDAQ:ADHD.DL VS S&P 500 (SPY)

NASDAQ:ADHD.DL Summary

  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about ADHD.DL.

No one has written a Pitch for ADHD.DL stock yet. Tell us why you think ADHD.DL will outperform or underperform against the market.

Leaderboard

Find the members with the highest scoring picks in ADHD.DL.

No players have picked ADHD.DL yet. Tell us why you think ADHD.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ADHD.DL.